Placement of Trials Increasingly Dispersed
The distribution of locations for all trials registered on ClinicalTrials.gov.
The percentage of registered clinical trials being conducted at investigative sites outside of the U.S. continues to rise. According to data provided by http://ClinicalTrials.gov/ on the distribution of locations for all trials registered on the website, 45% reside in non-U.S. geographies.
The U.S., of course, continues to be the most active location for clinical research by size, with the country still home to 40% of all registered studies in the world. Six percent, or 10,572, of those trials in the http://ClinicalTrials.gov/ database have sites located in the U.S. as well as other global regions.
As of Sept. 23, a href="http://www.ClinicalTrials.gov" target="_blank" rel="nofollow">http://ClinicalTrials.gov/ included entries on 175,249 studies, with locations in 187 countries.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
